Plasma esterases in cystic fibrosis: The impact of a respiratory exacerbation and its treatment

European Journal of Clinical Pharmacology

Volumn 54, Issue 12, 1999, Pages 937-941

  Abou Hatab, K ^a   Nixon, L S ^a   O'Mahony, M S ^a   Newsway, V ^a   Patel, S ^a   Shale, D J ^a   Woodhouse, K W ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Cystic fibrosis; Drug metabolism; Esterases

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CHOLINESTERASE; ESTERASE; INTERLEUKIN 6; LEUKOCYTE ELASTASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC THERAPY; ARTICLE; CHOLINESTERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT INFECTION; SPECTROPHOTOMETRY;

EID: 0033009002     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050578     Document Type: Article

References (40)

1. Renton KW, Knickle LC (1990) Regulation of hepatic cytochrome P-450 during infectious disease. Can J Physiol Pharmacol 68: 777-81
2. Renton KW, Mannering GJ (1976) Depression of hepatic cytochrome P450-dependent monooxygenase systems with administered interferon inducing agents. Biochem Biophys Res Commun 73: 343-348
3. Soyka LF, Hunt WG, Knight SE, Foster RSJR (1976) Decreased liver and lung drug-metabolizing activity in mice treated with Corynebacterium parvum. Cancer Res 36: 4425-4428
4. Mannering GJ, Deloria LB (1986) The pharmacology and toxicology of the interferons: an overview. Annu Rev Pharmacol Toxocol 26: 455-515
5. Parkinson A, Lasker J, Kramer MJ, Huang MT, Thomas PE, Ryan DE, Reik IM, Norman RL, Levin W, Conney AH (1982) Effects of three recombinant human leukocyte interferons on drug metabolism in mice. Drug Metab Dispos 10: 579-585
6. Franklin MR, Finkle BS (1985) Effect of murine gamma-interferon on the mouse liver and its drug-metabolizing enzymes: comparison with human hybrid alpha-interferon. J Interferon Res 5: 265-272
7. Anari MR, Renton KW (1993) Modulatory effect of hyperthermia on hepatic microsomal cytochrome P450 in mice. Biochem Pharmacol 46: 307-310
8. Chang KC, Bell TD, Laurer BA, Chai H (1978) Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1: 1132-1133
9. Fleetham JA, Nakatsu K, Munt PW (1978) Theophylline pharmacokinetics and respiratory infections. Lancet 2: 898
10. Clark CJ, Boyd G (1979) Theophylline pharmacokinetics during respiratory viral infection. Lancet 1: 492.
11. Friesen CA, Wiens LA, Burry VF, Portnoy J, Roberts C (1995) C-reactive protein in acute pulmonary exacerbations of patients with cystic fibrosis. Pediatr Pulmon 20: 215-219
12. Elborn JS, Cordon SM, Parker D, Delamere FM, Shale DJ (1993) The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Respir Med 87: 603-607
13. Elborn JS, Cordon SM, Western P, Macdonald IA, Shale DJ (1993) TNFα, resting energy expenditure and cachexia in cystic fibrosis. Clin Sci 85: 563-568
14. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ (1998) Circulating immunoreactive interleukin 6 (IL-6) in cystic fibrosis. Am J Respir Crit Care Med 157: 1-6.
15. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B (1984) Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 105: 117-124
16. Leeder JS, Spino M, Isles AF, Tesoro AM, Gold R, MacLeod SM (1984) Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther 36: 355-362
17. Jusko WJ, Mosovich LL, Gerbracht LM, Mattar ME, Yaffe SJ (1975) Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics 56: 1038-1044
18. Wang JP, Unadkat JD, McNamara S, O'Sullivan TA, Smith AL, Trager WF, Ramsey B (1994) Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. Clin Pharmacol Ther 55: 528-534
19. Isles A, Spino M, Tabachnik E, Levison H, Thiessen J, MacLeod S (1983) Theophylline disposition in cystic fibrosis. Am Rev Respir Dis 127: 417-421
20. Williams FM (1987) Serum enzymes of drug metabolism. Pharmacol Ther 34: 99-109
21. Seymour RA, Williams FM, Ward A, Rawlins MD (1984) Aspirin metabolism and efficacy in postoperative dental pain. Br J Clin Pharmacol 17: 697-702
22. O'Mahony MS, George G, Westlake H, Woodhouse K (1994) Plasma esterase activity in elderly patients undergoing elective hip replacement and with fractured neck of femur. Age Ageing 23: 338-341
23. Kalow W, Lindsay HA (1955) A comparison of optical manometric methods for the assay of human serum cholinesterase. Can J Biochem Physiol 33: 568-574
24. Ellman GL, Courtney KD, Andress V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95
25. Kearns GL, Mallory GB Jr, Crom WR, Evans WE (1990) Enhanced hepatic drug clearance in patients with cystic fibrosis. J Pediatr 117:972-979
26. Sonne J, Dossing M, Loft S, Andreasen PB (1985) Antipyrine clearance in pneumonia. Clin Pharmacol Ther 37: 701-704
27. Soons PA, Grib C, Breimer DD, Kirch W (1992) Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol. Clin Pharmacokinet 23: 238-248
28. Pous C, Giroud JP, Damais C, Raichvarg D, Chauvelot-Moachon L (1990) Effect of recombinant human interleukin-1β and tumor necrosis factor-α on liver cytochrome P-450 and serum α1-acid glycoprotein concentrations in the rat. Drug Metab Dispos 18: 467-470
29. Parmentier JH, Kremers P, Ferrari L, Batt AM, Gielen JE, Siest G (1993) Repression of cytochrome P450 by cytokines: IL-1 beta counteracts clofibric acid induction of CYP4A in cultured fetal rat hepatocytes. Cell Biol Toxicol 9: 307-313
30. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A (1993) Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44: 707-715
31. Park GR, Pichard L, Tinel M, Larroque C, Elston A, Domerque J, Dexionne B, Maurel P (1994) What changes drug metabolism in critically ill patients? Two preliminary studies in isolated human hepatocytes. Anaesthesia 49: 188-189
32. Chen YL, Le Vraux V, Leneveu A, Dreyfus F, Stheneur A, Florentin I, De Sousa M, Giroud JP, Flouvat B, Chauvelot-Moachon L (1994) Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 5: 649-660
33. Baraka A, Wakid N, Noueihed R, Karam H, Bolotova N (1986) Pseudocholinesterase activity and atracurium v. suxamethonium block. Br J Anaesth 58 Suppl 1: 91S-95S
34. Gyasi HK, Mohy O, Adu-Gyamfi Y, Naguib M (1986) Plasma cholinesterase in pregnancy - effect of enzyme activity on the duration of action of succinylcholine. Middle East J Anesthesiol. 8[5]: 379-385
35. Jensen FS, Viby-Mogensen J, Ostergaard D (1991) Significance of plasma cholinesterases for the anaesthetist. Curr Anaesth Crit Care 2: 232-237
36. Viby-Mogensen J, Hanel HK, Hansen E, Graae J (1975) Serum cholinesterase activity in burned patients. II: anaesthesia, suxamethonium and hyperkalaemia. Acta Anaesthesiol Scand 19[3]: 169-179
37. Pedersen NA, Jensen FS (1994) Clinical importance of plasma cholinesterase for the anaesthetist. Ann Acad Med Singapore 23 [Suppl]: 120S-124S
38. Viby-Mogensen J (1980) Correlation of succinylcholine duration of action with plasma cholinesterase activity in subjects with the genotypically normal enzyme. Anesthesiology 53[6]: 517-520
39. Vanlinthout LEH, Van Egmond J, De Boo T, Lerou JGC, Wevers RA, Booij LHDJ (1992) Factors affecting magnitude and time course of neuromuscular block produced by suxamethonium. Br J Anaesth 69[1]: 29-35
40. Davis L, Britten JJ, Morgan M (1997) Cholinesterase. Its significance in anaesthetic practice. Anesthesia 52[3]: 244-260